结直肠癌
生物
癌症研究
Wnt信号通路
融合基因
癌症
基因
微卫星不稳定性
突变
免疫疗法
连环蛋白
MAPK/ERK通路
突变体
腺癌
酪氨酸激酶
受体酪氨酸激酶
肿瘤科
内科学
融合蛋白
医学
激酶
基因组学
抑癌基因
靶向治疗
外科肿瘤学
基因家族
作者
Michael Bonner Foote,Guilherme Harada,Somer Abdelfattah,Nil Urgancı,Paolo Manca,Jinru Shia,Henry S. Walch,Guillem Argilés,Oliver Artz,Rona Yaeger,Maliha Nusrat,Shrey Patel,Paul M. Johannet,Emily C. Harrold,Benoît Rousseau,Zsofia Stadler,Callahan M. Wilde,Vetri Sudar Jayaprakasam,Chiara Cremolini,Sara Lonardi
标识
DOI:10.1158/1078-0432.ccr-26-0024
摘要
PURPOSE: Mismatch repair-deficient (MMRd) colorectal cancers are classified based on MMR protein loss and BRAFV600E mutations. BRAF wild-type sporadic MMRd tumors exhibit a diverse landscape of alternative oncogenes, including gene fusions, with unclear biological and clinical significance. We evaluated mutually exclusive subtypes of sporadic MMRd tumors defined by oncogenic mitogen-activated protein kinase (MAPK) variants and gene fusions to determine the relationship among predominant genomic driver, MMR deficiency mechanism, and clinical outcomes. EXPERIMENTAL DESIGN: We assessed 6,789 patients with colorectal cancer sequenced by MSK-IMPACT to identify 518 patients with sporadic MMRd colorectal cancer. We defined mutually exclusive oncogenic alteration subtypes and then assessed differences in allele-specific MMR-inactivating events, co-occurring oncogenic variants, and patient outcomes. We validated findings in an Italian cohort (n = 69). RESULTS: We identify 4 sporadic MMRd colorectal cancer subtypes: (i) oncogenic fusion-positive, (ii) RAS-mutant (mut), (iii) BRAFV600E-mut, and (iv) MAPK/fusion driver-negative. These mutually exclusive subtypes were associated with conserved molecular lineages of MMR gene inactivation and WNT signaling variants. Oncogenic fusions were disproportionately prevalent in non-Caucasians, among nonsmokers, and in the transverse colon, compared with subtypes that were enriched in smokers (BRAF-mut) and male, younger patients (RAS-mut and MAPK/fusion-driverless). Oncogene-defined molecular lineages were strong predictors of patient outcomes and response to immunotherapy and tyrosine kinase inhibition for metastatic disease. Fusion-positive patients demonstrated improved survival compared with BRAF-mut cancers and benefited from immunotherapy and fusion inhibitors. MAPK/fusion driver-negative tumors were aneuploid, responded poorly to immunotherapy, and were sensitive to EGFR blockade. CONCLUSIONS: Overall, MAPK and fusion oncogenic drivers distinguish MMRd colorectal cancer molecular lineages that inform molecular and clinical phenotypes.
科研通智能强力驱动
Strongly Powered by AbleSci AI